Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy.
Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy.
复制标题
DOI：
10.1182/blood.v80.4.1090.bloodjournal8041090
复制
发表时间：
1992-08
期刊：
影响因子：
20.3
通讯作者：
J. Biggs;M. Horowitz;R. Gale;R. Ash;K. Atkinson;W. Helbig;N. Jacobsen;Gordon;Phillips;A. Rimm;O. Ringdén;C. Rozman;K. Sobocinski;J. Veum;M. Bortin
中科院分区：
文献类型：
--
作者：
J. Biggs;M. Horowitz;R. Gale;R. Ash;K. Atkinson;W. Helbig;N. Jacobsen;Gordon;Phillips;A. Rimm;O. Ringdén;C. Rozman;K. Sobocinski;J. Veum;M. Bortin
约30%的成人急性淋巴细胞白血病(ALL)和20%-40%的儿童和成人急性髓系白血病(AML)即使在强化化疗后也从未得到缓解。大多数人死于耐药白血病，通常在6个月或更短的时间内死亡。在这项对126名耐药ALL或AML患者的研究中，115名可评估患者中的113名(98%)接受了来自人类白细胞抗原相合同胞的异基因骨髓移植。3年无白血病生存率为21%(95%可信区间，15%~29%)。ALL(23%，12%至40%)和AML(21%，14%至31%)的无白血病生存率相似。在27名有风险的患者中，只有3人在移植后2年以上复发。
About 30% of adults with acute lymphoblastic leukemia (ALL) and 20% to 40% of children and adults with acute myelogenous leukemia (AML) never achieve remission, even with intensive chemotherapy. Most die of resistant leukemia, often within 6 months or less. In this study of 126 patients with resistant ALL or AML, allogeneic bone marrow transplants from HLA-identical siblings produced remissions in 113 of 115 (98%) evaluable patients. The 3-year probability of leukemia-free survival was 21% (95% confidence interval, 15% to 29%). Leukemia-free survival was similar in ALL (23%, 12% to 40%) and AML (21%, 14% to 31%). Only 3 of 27 patients at risk relapsed more than 2 years posttransplant.